ロード中...
Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience
BACKGROUND: The recombinant factor VIII (rFVIII)-IgG1 Fc fusion protein (rFVIII-Fc) was the first available extended half-life rFVIII, shown to prolong dosing intervals of individualised prophylaxis in patients with severe haemophilia A, maintaining low bleeding rates and unchanged or lower FVIII do...
保存先:
| 出版年: | Blood Transfus |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Edizioni SIMTI - SIMTI Servizi Srl
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7592167/ https://ncbi.nlm.nih.gov/pubmed/31855153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2450/2019.0220-19 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|